Free tool
FAERS Monitor: Strensiq
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125513 or its brand name (Strensiq, Asfotase Alfa). Reports on generic versions are filed under their own applications.
Reports
10,322
Serious
3,394
33% of reports
Hospitalization
799
Death reported
79
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- injection site pain1,351
- fatigue1,029
- injection site erythema881
- pain851
- injection site reaction778
- arthralgia713
- pain in extremity564
- injection site bruising513
- injection site swelling442
- headache416
- injection site pruritus344
- bone pain323
- blood alkaline phosphatase increased319
- nausea313
- malaise307
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 33 |
| 2016 | 785 |
| 2017 | 1,088 |
| 2018 | 1,301 |
| 2019 | 1,057 |
| 2020 | 259 |
| 2021 | 206 |
| 2022 | 172 |
| 2023 | 714 |
| 2024 | 2,432 |
| 2025 | 1,084 |
| 2026 | 1,191 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,837 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood alkaline phosphatase increasedSignal | 319 | 26.5 | 23.8 | 7,716 |
| injection site reactionSignal | 778 | 23.3 | 21.8 | 16,442 |
| injection site erythemaSignal | 881 | 14.6 | 13.7 | 11,106 |
| injection site bruisingSignal | 513 | 13.2 | 12.1 | 5,748 |
| injection site swellingSignal | 442 | 11.8 | 10.8 | 4,356 |
| bone painSignal | 323 | 11.3 | 10.1 | 3,012 |
| injection site pruritusSignal | 344 | 10.5 | 9.5 | 2,946 |
| injection site painSignal | 1,351 | 9.0 | 8.6 | 9,712 |
| pain in extremitySignal | 564 | 3.9 | 3.6 | 1,231 |
| arthralgiaSignal | 713 | 3.5 | 3.3 | 1,293 |
| painSignal | 851 | 2.8 | 2.6 | 1,031 |
| fatigueSignal | 1,029 | 2.7 | 2.5 | 1,136 |
| malaise | 307 | 1.4 | 1.3 | 40 |
| headache | 416 | 1.4 | 1.2 | 39 |
| nausea | 313 | 0.8 | 0.7 | 15 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.